Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Systems Biology in Biotech & PharmaDevelopment: Pharmacokinetics—Systems Biology in Health and Disease III

Systems Biology in Biotech & Pharma: Development: Pharmacokinetics—Systems Biology in Health and... [In silico PKPD/ADMET and biochemical-mechanistic methods will become a standard approach in the coming few years via the employment of BI and SB tools at the multiscale whole-body level. So far, the overall impact of toxicity markers on preclinical safety testing has been modest. The greatest benefit of PBPK models is they may allow for individualized health care.] http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png

Systems Biology in Biotech & PharmaDevelopment: Pharmacokinetics—Systems Biology in Health and Disease III

Loading next page...
 
/lp/springer-journals/systems-biology-in-biotech-pharma-development-pharmacokinetics-systems-oJARVDG0Nm

References (26)

Publisher
Springer Netherlands
Copyright
© The Author(s) 2012
ISBN
978-94-007-2848-6
Pages
77 –85
DOI
10.1007/978-94-007-2849-3_7
Publisher site
See Chapter on Publisher Site

Abstract

[In silico PKPD/ADMET and biochemical-mechanistic methods will become a standard approach in the coming few years via the employment of BI and SB tools at the multiscale whole-body level. So far, the overall impact of toxicity markers on preclinical safety testing has been modest. The greatest benefit of PBPK models is they may allow for individualized health care.]

Published: Jan 4, 2012

Keywords: PBPK Modeling; Adaptive Design; Accelerator Mass Spectrometry; Toxicological Endpoint; Toxicity Prediction

There are no references for this article.